Abstract
This study was performed to evaluate a potential of ribavirin for inhibiting Batai virus replication in vitro. Ribavirin manufactured by ICN Switzerland AG (Switzerland) was used for the study. The drug and specific immune ascitic fluid were added to a cell culture (Vero E6)1 hour after the virus-to-cell contact at 37 °C. Ribavirin was also added 1 hour before and 2, 4, 6 and 18 hours after the virus-cell contact. This study first showed that ribavirin significantly inhibited Batai virus replication in vitro.
-
1.
Белов А.В., Ларичев В.Ф., Галкина И.В., Хуторецкая Н.В., Бутенко А.М. и др. Активность отечественного рибавирина в опытах in vitro на моделях вирусов крымской геморрагической лихорадки, лихорадки долины Рифт, Тягиня и Дхори. Вопр вирусол 2008; (1):34-5.
-
2.
Константинова И.Д., Есипов Р.С., Муравьёва Т.И. и др. Способ получения 1-β-D-рибофуранозил-1,2,4-триазол-3-карбоксамида (рибавирин). Пат. РФ № 2230118 от 21.08.2002 г.
-
3.
Enria V.A., Maiztegui S.L. Antiviral treatment of Argentine hemorrhagic fever. Antiviral Res 1994; 23:23- 31.
-
4.
Huggins J.W., Cosgriff T.M., Smith J.I. Interruption study of viremia of patients with hemorrhagic fever with renal syndrome in the febrile phase. Chin Med J 1991; 104:149-53.
-
5.
Sidwell R.W., Huffman J.H., Barnett B.B., Pifat D.Y. In vitro and in vivo phlebovirus inhibition by ribavirin. Antimicrob Agents Chemother 1988; 32:331-6.